Cargando…

Recent advances in therapeutic strategies for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yun, Zhang, Huajun, Merkher, Yulia, Chen, Lin, Liu, Na, Leonov, Sergey, Chen, Yongheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422136/ https://www.ncbi.nlm.nih.gov/pubmed/36038913 http://dx.doi.org/10.1186/s13045-022-01341-0

Ejemplares similares

Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer
por: Lu, Liqing, et al.
Publicado: (2022)

Recent advances in targeted strategies for triple-negative breast cancer
por: Zhu, Shuangli, et al.
Publicado: (2023)

Proteomic Markers for Mechanobiological Properties of Metastatic Cancer Cells
por: Leonov, Sergey, et al.
Publicado: (2023)

Anti-Cancer Properties of Flaxseed Proteome
por: Merkher, Yulia, et al.
Publicado: (2023)

Recent advances in managing triple-negative breast cancers
por: Bengala, Carmelo
Publicado: (2009)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
por: Medina, Mauricio A., et al.
Publicado: (2020)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Recent advances in nanotheranostics for triple negative breast cancer treatment
por: Thakur, Vikram, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Recent advances in systemic therapy for hepatocellular carcinoma
por: Zhang, Huajun, et al.
Publicado: (2022)

Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
por: Pradhan, Rajesh, et al.
Publicado: (2023)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Encapsulation and adhesion of nanoparticles as a potential biomarker for TNBC cells metastatic propensity
por: Merkher, Yulia, et al.
Publicado: (2023)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

Recent Clinical Advances on Long Non-Coding RNAs in Triple-Negative Breast Cancer
por: Singh, Desh Deepak, et al.
Publicado: (2023)

Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
por: Khadela, Avinash, et al.
Publicado: (2022)

Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
por: Chalakur-Ramireddy, Naveen K.R., et al.
Publicado: (2018)

The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022)

Ferroptosis and triple-negative breast cancer: Potential therapeutic targets
por: Xu, Na, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
por: El Hachem, Georges, et al.
Publicado: (2019)

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Wang, Chao-Qun, et al.
Publicado: (2017)

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Revealing targeted therapeutic opportunities in triple-negative breast cancers: A new strategy
por: Poage, Graham M, et al.
Publicado: (2013)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
por: Li, Shuanghe, et al.
Publicado: (2022)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Recent advances in peptide-based therapeutic strategies for breast cancer treatment
por: Li, Ling, et al.
Publicado: (2023)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Triple negative breast cancer: special histological types and emerging therapeutic methods
por: Cao, Lu, et al.
Publicado: (2020)

Interfering MSN-NONO complex–activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer
por: Qin, Yuanyuan, et al.
Publicado: (2020)

Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer
por: Shi, Jinhong, et al.
Publicado: (2020)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h8uiedc6lfqjvv0igsas8ci2mi